Lundbeck has halted its TED study on the eve of a bexicaserin phase 3 readout, according to the latest update tied to the company’s broader epilepsy program. The pause comes just after Lundbeck completed randomization for the phase 3 trial ahead of schedule. Bexicaserin is being positioned as a potential blockbuster 5-HT2C agonist in epilepsy, with top-line results expected in the fourth quarter. The halt introduces uncertainty around timing and endpoint interpretation for the planned readout. The move also intersects with Lundbeck’s $2.6 billion acquisition of Longboard Pharmaceuticals, which is bringing its first major clinical-test milestone into focus. For the sector, the development is a reminder that operational decisions close to readouts can materially shift timelines and risk assessments for CNS pipeline assets.